DDInter624 DDInter832
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
A trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism.
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inhibitors
Efavirenz {u} (Compound) downregulates {v} (Gene) POLR2I
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatitis
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease)
Efavirenz (Compound) binds CYP2C19 (Gene)
Efavirenz (Compound) upregulates IKBKB (Gene)
Efavirenz (Compound) is included by Cytochrome P450 2C19 Inhibitors (Pharmacologic Class)
Efavirenz (Compound) downregulates POLR2I (Gene)
Efavirenz (Compound) causes Hepatitis (Side Effect)